7HC SOCIETA A RESPONSABILITA LIMITATA

Their core work

7HC is a small Italian technology company based in Rome that brings computational modelling and AI-driven decision support capabilities to interdisciplinary research consortia. In VIRTUOUS, they contributed to molecular dynamics and bioinformatics work aimed at computationally predicting how food compounds interact with human taste receptors. In PARENT, they shifted application domain entirely — applying AI, mechanistic modelling, and decision support systems to the early diagnosis of motor and cognitive impairments in premature newborns. Their value proposition appears to be domain-agnostic computational intelligence: the underlying methods (molecular modelling, AI inference, biomarker analysis) travel across fields, from food science to paediatric neurology.

What they specialise in

How they've shifted over time

7HC entered H2020 through the lens of computational food science: their first project (VIRTUOUS, 2019) was grounded in molecular dynamics, bioinformatics, and the prediction of taste and dietary interactions at the protein level. By 2020, with PARENT, they moved into paediatric clinical research — neuroimaging, eye tracking, congenital heart disease, and AI-assisted early diagnosis of cerebral palsy. This is not a gradual drift but a domain jump, which suggests the company's core asset is the modelling and AI methodology itself, not deep sector expertise in either food or neonatology. The trajectory points toward health and clinical applications as the more recent and financially significant direction.

7HC appears to be repositioning toward health and clinical AI applications, with their most recent and best-funded project addressing unmet diagnostic needs in neonatal medicine — a sector with strong EU research investment and growing demand for AI-assisted tools.

How they like to work

7HC has participated exclusively as a consortium partner, never as a project coordinator, across both projects. They join mid-to-large MSCA consortia (RISE and ITN schemes typically involve 6–15 partners), suggesting they are brought in as specialist contributors rather than project drivers. With 19 unique partners across only 2 projects, their network is reasonably broad relative to their project count, indicating they have been embedded in active, well-connected consortia rather than isolated collaborations.

Despite only two projects, 7HC has worked with 19 distinct partner organisations across 7 countries, indicating exposure to internationally diverse consortia typical of MSCA schemes. No repeated partners are detectable in this dataset, so there is no evidence of a recurring inner circle.

What sets them apart

7HC's distinguishing feature is the application of computational modelling and AI tooling across radically different biological domains — from food taste science to neonatal brain injury — within just two projects. For a consortium builder, this signals a company whose methods are platform-level rather than domain-locked, making them a potentially flexible technical partner when the project requires AI inference, mechanistic simulation, or biomarker analytics in a life science context. As a Roman SME participating in MSCA schemes, they also bring Italian industry representation useful for consortia seeking geographic or sector diversity.

Highlights from their portfolio

• PARENT
  The largest project by far (€261,500 EC contribution, 2020–2025), addressing a high-impact clinical problem — early diagnosis of cerebral palsy and cognitive impairment in premature newborns — using AI and multimodal neuroimaging, placing 7HC in a medically and socially significant research area.
• VIRTUOUS
  An unusual interdisciplinary project combining molecular dynamics, bioinformatics, and food science to build a computational 'virtual tongue' for predicting how Mediterranean diet ingredients affect human homeostasis — a niche but commercially interesting research direction.